MGRX Mangoceuticals, Inc.

Healthcare

$0.45+2.97%ClosedMarket Cap: $4.6M

As of 2026-05-25

Valuation

P/E (TTM)

—

PEG

—

P/B

0.34

P/S

11.02

EV/EBITDA

-0.27

DCF Value

$0.08

FCF Yield

-106.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

52.4%

Operating Margin

-4203.8%

Net Margin

-4632.9%

ROE

-120.7%

ROA

-132.9%

ROIC

-126.6%

Financials

Period	Revenue	Net Income	EPS
Q1 null	$67.9K	$-3.4M	$—
Q4 null	$94.4K	$-2.8M	$—
FY null	$456.0K	$-20.6M	$—
Q3 null	$84.2K	$-7.6M	$—

Trading Activity

Insider Trades

Cohen Jacob D.director, 10 percent owner, officer: Chief Executive Officer

SellFri Mar 20

Cohen Jacob D.director, 10 percent owner, officer: Chief Executive Officer

SellFri Mar 20

Cohen Jacob D.director, 10 percent owner, officer: Chief Executive Officer

SellFri Mar 20

Cohen Jacob D.director, 10 percent owner, officer: Chief Executive Officer

SellFri Mar 20

Cohen Jacob D.director, 10 percent owner, officer: Chief Executive Officer

SellFri Mar 20

Company Info

Sector

Healthcare

Industry

Medical - Healthcare Information Services

Country

US

Exchange

—

Beta

2.12

Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Peers